



MRN: \_\_\_\_\_

Phone: 1-800-809-1265 Fax: 1-866-872-8920

DOB: \_\_\_\_\_

**STANDARD INFLECTRA® (infliximab-dyyb) PLAN OF TREATMENT FOR RHEUMATOLOGY**

**NOTE:** Patient **may be ineligible** to receive (infliximab-dyyb) if receiving antibiotics for active infectious process, antifungal therapy, active fever and/or suspected infection, new or worsening symptoms of CHF, new-onset or deterioration neurological changes, and/or surgery.

**1. Patient Name:** \_\_\_\_\_ Height (inches): \_\_\_\_\_ Weight (lbs): \_\_\_\_\_

**2. Allergies:** \_\_\_\_\_

**3. Diagnosis:** \* Please complete the 2<sup>nd</sup> and 3<sup>rd</sup> digits to complete the ICD-10 code for billing

**M05.**\_\_\_\_\_ Rheumatoid Arthritis with Rheumatoid factor  **M06.**\_\_\_\_\_ Rheumatoid Arthritis without Rheumatoid factor

**L40.5**\_\_\_\_\_ Psoriatic Arthropathy  **M45.**\_\_\_\_\_ Ankylosing Spondylitis  **D86.0** Sarcoidosis of the Lung

Other **ICD-10 Code:** \_\_\_\_\_ **Diagnosis description:** \_\_\_\_\_

**4. Pre-medications:** Administered 30 minutes prior to infusion as selected:

*\*Product information suggests premedication of antihistamines, acetaminophen, and/or corticosteroids.*

<p>a) Acetaminophen:</p> <p><input type="checkbox"/> 650mgs PO</p> <p><input type="checkbox"/> 500mgs PO</p> <p><input type="checkbox"/> 325mgs PO</p>	<p>b) Diphenhydramine: <input type="checkbox"/> 25 mgs PO, <input type="checkbox"/> 50mgs PO, <input type="checkbox"/> 25 mgs IVP, <input type="checkbox"/> 50mgs IVP or</p> <p>c) Alternate oral antihistamine to diphenhydramine:</p> <p><input type="checkbox"/> Cetirizine 10 mg, <input type="checkbox"/> Loratadine 10 mg, Fexofenadine <input type="checkbox"/> 60mgs or <input type="checkbox"/> 180mgs</p> <p>d) Other: Methylprednisolone <input type="checkbox"/> 40mgs IVP <input type="checkbox"/> 125mgs IVP or other _____mgs IVP</p> <p>Famotidine: <input type="checkbox"/> 20mgs PO, <input type="checkbox"/> 40mgs PO, <input type="checkbox"/> 20mgs IVP, <input type="checkbox"/> 40mgs IVP</p>
--	--

e) Pre-medicate with other: \_\_\_\_\_

*CONFIDENTIAL Property of Palmetto Infusion / CONFIDENTIAL Property of Palmetto Infusion / CONFIDENTIAL Property of Palmetto Infusion*

**If adverse drug reaction occurs, utilize the ADVERSE DRUG REACTION GUIDELINES.**

**5. Order:**  INFLECTRA®(infliximab-dyyb) 3 mg/kg per 250 ml Sodium Chloride 0.9% IV to infuse over at least 2 hours **OR**

Other Dose: \_\_\_\_\_mg or \_\_\_\_\_mg/kg per 250 - 500 ml Sodium Chloride 0.9% IV

**6. Frequency:**  Induction orders to be completed at 0 week, 2 week, and 6 weeks

Maintenance Orders every 8 weeks

Special Orders: \_\_\_\_\_

Lab orders with infusions: \_\_\_\_\_

**7. Physician's Signature:** \_\_\_\_\_ / \_\_\_\_\_ Date: \_\_\_\_\_

No Stamp Signatures

(Dispense as written)

(Substitution permitted)

Printed Physician's Name with Credentials: \_\_\_\_\_

**8. Fax updated supporting clinical MD notes with each order renewal or change in orders**

*Infusion order forms available at [www.palmettoinfusion.com](http://www.palmettoinfusion.com)*



MRN: \_\_\_\_\_  
 DOB: \_\_\_\_\_

**Phone: 1-800-809-1265 Fax: 1-866-872-8920**

**Guidelines for Prescribing INFLECTRA® (infliximab-dyyb) for Rheumatology**  
 (Required documentation with all initial referrals)

**Patient Name:** \_\_\_\_\_ **Referral Date:** \_\_\_\_\_

- \_\_\_\_\_ Include signed and completed **Plan of Treatment**. (MD must complete sections 1-8)  
 (Infusion order forms & Standard Adverse Reactions orders are available at [www.palmettoinfusion.com](http://www.palmettoinfusion.com) under Agency/MD tab)
- \_\_\_\_\_ Include patient demographic information and insurance information. (Copy of insurance cards if available)
- \_\_\_\_\_ **Supporting clinical MD notes to include any past tried and/or failed therapies, intolerance, outcomes or contraindications to conventional therapy. Include any lab results and/or tests to support diagnosis.**  
**INFLECTRA® is a biosimilar to Remicade® that is indications for:**
  - **Rheumatoid Arthritis in combination with methotrexate:** reduces signs and symptoms, inhibits the progression of structural damage, and improves physical function in patients with moderately to severely active disease. Dose in conjunction with methotrexate of 3 mg/kg at 0, 2 and 6 weeks, then every 8 weeks. Some patients may benefit from increasing the dose up to 10 mg/kg or treating as often as every 4 weeks.
  - **Ankylosing Spondylitis:** indicated for dosing at 5 mg/kg induction & then every 6 weeks.
  - **Psoriatic Arthritis & Plaque Psoriasis:** indicated for dosing at 5 mg/kg induction & then every 8 weeks.
- \_\_\_\_\_ If patient is switching biological therapies, then MD must specify wash-out period prior to starting INFLECTRA® as specified of \_\_\_\_\_ weeks. Last known biological therapy: \_\_\_\_\_ and last date received: \_\_\_\_\_. (Include copy of last INFLECTRA® infusion record if available and currently on therapy)
- \_\_\_\_\_ Other as requested: \_\_\_\_\_

**Pre-Screening: (TB and Hepatitis screening results must be available prior to start of therapy and within last 12 months.)**

- \_\_\_\_\_ **Required TB screening results: PPD or QuantiFERON Gold Test.**  
 (\* If screening results are positive or indeterminate, then a negative CXR result is required.)
- \_\_\_\_\_ **Required Hepatitis screening to include: Hepatitis B Surface Antigen results.**

**\*\* Warnings/Precautions: \*Product information suggests that patients who have stopped treatment for an extended period are at higher risk for hypersensitivity reactions. MD should evaluate premedication and consider antibody testing prior to restart of infliximab or biosimilar.** Patient should not have an active ongoing infection, signs or symptoms of malignancy, or invasive fungal infection. Do not initiate INFLECTRA® therapy in patients with moderate to severe Congestive Heart Failure. **INFLECTRA® at doses of >5 mg/kg should not be administer to patients with moderate to severe heart failure.** Patient with mild CHF should be closely monitored. Therapy should be discontinued in patients who develop new or worsening symptoms of heart failure. **Hepatotoxicity:** Stop therapy in case of jaundice and/or marked liver enzyme elevations. Evaluation of immunizations should be completed prior to and live vaccines should not be given before or concurrently with INFLECTRA®. See full prescribing information.

Palmetto Infusion Services will complete insurance verification and submit all required clinical documentation to the patient's insurance company for eligibility. Our office will notify you if any further information is required. We will review financial responsibility with the patient and refer them to any available Co-pay assistance as required. Thank you for the referral.

**Please fax all information to 1-866-872-8920 or call 1-800-809-1265 for assistance.**